Veracity Capital LLC Purchases Shares of 5,520 Gilead Sciences, Inc. (NASDAQ:GILD)

Veracity Capital LLC acquired a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) in the third quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 5,520 shares of the biopharmaceutical company’s stock, valued at approximately $463,000.

Several other large investors have also made changes to their positions in the company. Vanguard Group Inc. lifted its stake in shares of Gilead Sciences by 2.6% in the 1st quarter. Vanguard Group Inc. now owns 114,732,575 shares of the biopharmaceutical company’s stock valued at $8,404,161,000 after purchasing an additional 2,910,147 shares in the last quarter. Swedbank AB acquired a new position in Gilead Sciences during the first quarter valued at approximately $134,489,000. Capital Research Global Investors increased its position in shares of Gilead Sciences by 2.7% in the first quarter. Capital Research Global Investors now owns 61,246,366 shares of the biopharmaceutical company’s stock worth $4,486,296,000 after acquiring an additional 1,589,240 shares in the last quarter. Pacer Advisors Inc. raised its stake in shares of Gilead Sciences by 24.7% in the 2nd quarter. Pacer Advisors Inc. now owns 7,889,663 shares of the biopharmaceutical company’s stock valued at $541,310,000 after acquiring an additional 1,564,792 shares during the period. Finally, Deerfield Management Company L.P. Series C acquired a new position in shares of Gilead Sciences during the 2nd quarter valued at $102,298,000. 83.67% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

GILD has been the topic of several research reports. Evercore ISI raised Gilead Sciences to a “strong-buy” rating in a research report on Friday, August 9th. Sanford C. Bernstein assumed coverage on Gilead Sciences in a report on Thursday. They issued an “outperform” rating and a $105.00 price target for the company. Truist Financial increased their price objective on shares of Gilead Sciences from $82.00 to $83.00 and gave the company a “hold” rating in a research report on Thursday, August 15th. Wells Fargo & Company raised shares of Gilead Sciences from an “equal weight” rating to an “overweight” rating and boosted their target price for the stock from $78.00 to $100.00 in a research report on Monday, October 7th. Finally, BMO Capital Markets raised their price target on shares of Gilead Sciences from $85.00 to $94.00 and gave the company an “outperform” rating in a report on Thursday. Ten research analysts have rated the stock with a hold rating, ten have issued a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $86.37.

Gilead Sciences Stock Down 0.7 %

Shares of NASDAQ:GILD opened at $86.72 on Friday. The company’s fifty day moving average is $81.06 and its two-hundred day moving average is $72.81. The company has a debt-to-equity ratio of 1.18, a quick ratio of 0.95 and a current ratio of 1.14. Gilead Sciences, Inc. has a 1-year low of $62.07 and a 1-year high of $87.86. The stock has a market capitalization of $108.04 billion, a price-to-earnings ratio of 240.89, a price-to-earnings-growth ratio of 2.98 and a beta of 0.18.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, topping the consensus estimate of $1.61 by $0.40. Gilead Sciences had a net margin of 3.79% and a return on equity of 29.34%. The firm had revenue of $6.95 billion for the quarter, compared to analyst estimates of $6.64 billion. Equities analysts anticipate that Gilead Sciences, Inc. will post 3.78 EPS for the current year.

Gilead Sciences Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, September 27th. Investors of record on Friday, September 13th were paid a dividend of $0.77 per share. The ex-dividend date of this dividend was Friday, September 13th. This represents a $3.08 dividend on an annualized basis and a yield of 3.55%. Gilead Sciences’s payout ratio is currently 855.56%.

Insiders Place Their Bets

In other news, insider Johanna Mercier sold 5,490 shares of the business’s stock in a transaction on Tuesday, August 13th. The shares were sold at an average price of $73.98, for a total transaction of $406,150.20. Following the completion of the transaction, the insider now owns 114,979 shares of the company’s stock, valued at approximately $8,506,146.42. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other news, insider Johanna Mercier sold 5,490 shares of Gilead Sciences stock in a transaction that occurred on Tuesday, August 13th. The stock was sold at an average price of $73.98, for a total transaction of $406,150.20. Following the sale, the insider now owns 114,979 shares of the company’s stock, valued at approximately $8,506,146.42. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Merdad Parsey sold 2,000 shares of the stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $83.83, for a total value of $167,660.00. Following the completion of the transaction, the insider now directly owns 100,189 shares of the company’s stock, valued at $8,398,843.87. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 36,847 shares of company stock valued at $3,033,340 over the last three months. Company insiders own 0.16% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.